In addition, FGF2 and p-FGFR1 were highly expressed in FAPα+ HSCs in the co-opted sinusoidal blood vessels in bevacizumab-resistant HCT116 and HT-29 CRCLM xenografts (Supplemental Figure 6C), indicating that tumor cell–derived FGFBP1 might induce FAPα expression in HSCs by activating the FGF2/FGFR1 signaling pathway. The gene discussed is FGFR1; the disease is neoplasm.